Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ --Women today have a number of options when it comes to protecting their future health and possibly that of their families. Banking stem cells found in menstrual blood is one way in which women are looking to safeguard against potential future illnesses, conditions or injuries. Menstrual blood has been shown to contain self-renewing stem cells that may be stored for potential treatments in the future. A Florida-based company, Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL) offers C'elle, a service that empowers women to collect and preserve stem cells harvested from their own menstrual blood. Featured in a recent healthcare segment on ABC Action News in Tampa Bay, the promise of C'elle technology offers insightful perspectives from a C'elle client and from a stem cell researcher who is exploring development of Cryo-Cell's proprietary cutting edge technology for a potential neurological application.
Cryo-Cell discovered that menstrual flow contains millions of unique adult stem cells that demonstrate properties similar to bone marrow and embryonic stem cells. These stem cells have the potential to differentiate into possibly every other cell type in the human body. This finding represents an important step forward in adult stem cell discoveries, as it is the first time researchers have found an adult stem cell with these properties.
Menstrual stem cells (MenSCs) potentially offer compelling advantages over stem cells obtained from other sources because they can be easily obtained from women in a painless, non-invasive manner, and they are an exact match for the woman donor and therefore the patient's rejection of tissue may be avoided. Since menstrual stem cells are harvested from a source that would otherwise be regarded as biological waste, there are no ethical questions that are associated with embryonic stem cells.
Cryo-Cell has established numerous pre-clinical (non-human) research collaborations based on the expansive potential of C'elle menstrual stem cell technology to study a broad range of possible therapies to treat disorders including stroke, diabetes and vascular regeneration, among others. In 2008, the Company announced its collaboration with the National Institutes of Health (NIH), whose scientists are conducting an exploratory study of MenSCs for potential utilization in the treatment of breast cancer. This collective body of ongoing research may potentially change the types of therapies used to diagnose or treat a host of significant medical conditions in the future.
"We are clearly excited as Cryo-Cell continues to build a significant pipeline of strong research partnerships that are independently funded and that may possibly lead to breakthrough therapies for future human clinical studies," said Mercedes A. Walton, Chairman and CEO of Cryo-Cell. "We are also pleased to empower women with the opportunity to harvest and cryopreserve their own stem cells today for possible utilization in the future."
Cryo-Cell is one of the largest and most established family cord blood banks with nearly 185,000 clients worldwide. The first cord blood stem cell transplant occurred in 1988 and some twenty-one years later in 2009, over 12,000 cord blood stem cell transplants have taken place worldwide. To view the ABC News feature on C'elle visit: http://www.abcactionnews.com/content/taking_action_for_you/story/Is-the-stem-cell-controversy-coming-to-an-end/wbAmXpZW8EqVyrMkMiR8Hg.cspx
The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit http://www.Celle.com
About Cryo-Cell International, Inc. (OTCBB: CCEL.OB)
Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.
Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, including the C'elle service, given that menstrual stem cells and other new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are not likely to be developed and commercialized for many years and are subject to further research and development; the need for additional development and testing before determining the ultimate commercial value of the Company's intellectual property relating to the menstrual stem cells; the need to complete certain developments, including completion of clinical validation and testing, before any new process other than C'elle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.
Contact: General Media Inquiries Kristin O'Neill 312-233-1295 Kristin.Oneill@edelman.com Financial Media Inquiries: Cryo-Cell International, Inc. Investor Relations Dianne Will 518-398-6222 email@example.com
|SOURCE Cryo-Cell International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved